# Revumenib in Patients With Myelofibrosis

> **NCT07734077** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **John Mascarenhas** · enrollment: 32 (estimated)

## Conditions studied

- Myelofibrosis
- Post-polycythemia Vera Myelofibrosis
- Post-essential Thrombocythemia Myelofibrosis

## Interventions

- **DRUG:** Revumenib
- **DRUG:** Ruxolitinib
- **DRUG:** FEDRATINIB
- **DRUG:** Momelotinib

## Key facts

- **NCT ID:** NCT07734077
- **Lead sponsor:** John Mascarenhas
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-12-01
- **Primary completion:** 2028-12-01
- **Final completion:** 2028-12-01
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2026-07-29

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07734077

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07734077, "Revumenib in Patients With Myelofibrosis". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07734077. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*